Director, Multiple Myeloma Program, Medical Oncology
My research focuses on understanding the biology of multiple myeloma and development of novel therapeutics for the treatment of myeloma. On the basic front I have been involved with undersatnding the role of B cell activating factor (BAFF) and cyclin d dysregulation in myeloma. I am also involved with understanding the biology of bone disease in myeloma. On the translational front, we have several interesting antibodies and small molecules including BAFF antibody and cyclin D 1 inhibitors which have been validated preclinically and will be translated to phase I/II clinical studies for relapsed refractory myeloma.
None yet.